An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Completed · Phase 4 · NCT02596035
Conditions: Renal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $26,880
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 197
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (drug)
- Dates
- Started 2016-01-08; completion 2021-05-24
- Results posted
- Yes
This study will generate safety data on Nivolumab given by itself in treatment of advanced Renal Cell Carcinoma (RCC). The primary objective of this study is to assess immune related side effects, also known as immune-mediated adverse events (IMAEs), in patients treated with Nivolumab.
From ClinicalTrials.gov, last updated 2022-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $26,880 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Weill Medical College of Cornell University $26,880
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.